Journal
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 11, Issue 12, Pages 1421-1429Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156802611795860997
Keywords
Metabolic disorders; Cannabinoid 1 receptor; Peripheral antagonists; SR141716A
Categories
Funding
- National Health Research Institutes
- Axikin Pharmaceuticals, Inc.
Ask authors/readers for more resources
Since Rimonabant was withdrawn in Europe in 2008 because of its substantial CNS risk factors including depression and anxiety, the development of anti-obesity drugs targeting CB1R in the brain has been suspended and/or terminated globally. Instead, developing peripherally restricted CB1R antagonists is actively pursued in the hope that not only could they eliminate any CNS adverse effects observed with Rimonabant, but also maintain therapeutic benefits in metabolic syndrome, including obesity, type 2 diabetes, and non-alcoholic fatty liver diseases. In this review, we summarized the most recent advances that have been made on this area, with particular emphasis on various synthetic approaches, whereby the increase in polarity, water solubility and polar surface area were centralized on, toward potential peripheral-acting CB1 antagonists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available